## The landscape of metastatic progression patterns across major human cancers

## Supplementary Material

**Supplementary Table 1**: Overview of three different autopsy studies investigating metastatic disease progression across major cancer types.

	Autopsy studies on metastatic progression patterns across major human cancers			
General study characteristics	Abrams et al. (1950)	diSibio/French (2008)	Budczies et al. (2014)	
Major aims of the study	<ul> <li>description of metastatic patterns</li> </ul>	<ul> <li>description of metastatic patterns</li> </ul>	<ul> <li>description of metastatic patterns</li> <li>determination of the frequency of metastases</li> <li>prediction of primary sites</li> </ul>	
No. of cases analyzed	1000	3827	1008	
Period in which autopsies were performed	1943 – 1947	1914 – 1943	2000 – 2013	
Tumor origin	epithelial	epithelial	epithelial	
Treatment	n/a <sup>#</sup>	No chemotherapy or radiation	Surgery, chemotherapy, and radiation	
No. of primary cancers analyzed	18* (36)	41	16	
No. of metastasis sites analyzed	44	30	20	
Additional influencing factors investigated	-	-	<ul> <li>tobacco smoking</li> <li>histological type</li> </ul>	
Basic and comparable results of the analyses				
The most frequent primary cancers in the cohort investigated	<ol> <li>breast (16.7%)</li> <li>lung** (16.0%)</li> <li>stomach (11.9%)</li> <li>colon (11.8%)</li> <li>rectum (8.7%)</li> </ol>	<ol> <li>rectum (11.4%)</li> <li>breast (11.3%)</li> <li>cervix (10.9%)</li> <li>stomach (9.1%)</li> <li>prostate (5.0%)</li> </ol>	<ol> <li>lung (27.8%)</li> <li>esophagus/stomach</li> <li>(9.7%)</li> <li>colorectal cancer</li> <li>(8.8%)</li> <li>breast (8.8%)</li> <li>pancreas (7.7%)</li> </ol>	
The most frequent metastasis sites	1. abdom. LN (49.5%) 2. liver (49.4%) 3. lung (46.5%)	1. reg./dist. LN (20.5%/12.9%) 2. liver (11.1%)	1. liver (59%) 2. dist. LN (53%) 3. lung (44%)	

4. mediast. lymph	3. lung (10.7%)	4. bone (38%)
nodes (42.1%)	4. bone (6.5%)	

<sup>#</sup> Therapy data not provided in the paper

\* These entities account for about 95% of all cases.

\*\* No distinction between NSCLC and SCLC

LN = lymph nodes